Malignant Arrhythmia.
Conditions
Interventions
Hereditary Malignant Arrhythmia Group:None
Acquired Malignant Arrhythmia Group:None
Sponsors
Beijing Anzhen Hospital, Capital Medical University.
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-75 years old 2. Confirmed diagnosis of malignant arrhythmia with clear clinical evidence: diagnosed by electrocardiogram (ECG), Holter monitoring, imaging studies, genetic testing, etc. Specific diseases include: ventricular tachycardia (VT), ventricular fibrillation (VF), long QT syndrome (LQTS), short QT syndrome (SQTS), Brugada syndrome, history of cardiac arrest, or definite clinical manifestations of malignant arrhythmia (such as syncope).
Exclusion criteria
Exclusion criteria: 1. Presence of severe underlying diseases: Other uncontrollable severe cardiovascular diseases (such as severe heart failure, end-stage coronary artery disease), cancer, or other life-threatening conditions with a life expectancy =1 year. 2. Concurrent diseases affecting the study: Systemic diseases such as severe hepatic/renal failure or metabolic disorders that may interfere with the accuracy of biomarkers or omics data. 3. Refusal or inability to undergo long-term follow-up: Unwillingness to accept regular follow-up or unstable living conditions precluding long-term study participation. 4. Pregnant or lactating women. 5. Inability to understand or consent to the study: Patients with cognitive impairment or mental illness who cannot comprehend the study or sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular death; | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause death;Sudden cardiac death;Ventricular fibrillation;Sustained ventricular tachycardia; | — |
Countries
China
Contacts
Public ContactYunlong Wang
Beijing Anzhen Hospital, Capital Medical University.
Outcome results
None listed